ReportWire

Tag: Ozempic

  • Oprah Winfrey: Weight-loss drugs gave ‘hope’ after years of public ridicule – National | Globalnews.ca

    Oprah Winfrey: Weight-loss drugs gave ‘hope’ after years of public ridicule – National | Globalnews.ca

    [ad_1]

    After decades of being publicly ridiculed, shamed and scrutinized for her fluctuating weight, Oprah Winfrey said she is “really excited” about the availability of weight-loss medication.

    The media mogul’s latest one-off TV program, An Oprah Special: Shame, Blame, and the Weight Loss Revolution, aired Monday night.

    The hourlong broadcast saw Winfrey, 70, candidly discuss obesity and how weight-loss drugs have provided her with “hope.” Winfrey spoke highly of the medications — without mentioning specific name brands like Ozempic — and said she wanted to eliminate the “stigma and the shame and the judgment” around using weight-loss drugs.

    In front of a studio audience, Winfrey said she’s been berated for her weight throughout most of her career.

    “I have to say that I took on the shame that the world gave to me,” Winfrey said. “For 25 years, making fun of my weight was national sport.”

    Story continues below advertisement

    The talk show host recalled a 1990 cover of the magazine TV Guide that featured her photo and the accompanying headline: “Bumpy, lumpy, and downright dumpy.”

    Winfrey went on to read aloud several more disparaging tabloid headlines about her weight, including “Oprah: Fatter than ever” and “Oprah warned diet or die.”

    “In an effort to combat all the shame, I starved myself for nearly five months,” Winfrey revealed. “And after losing 67 pounds on a liquid diet, the next day, y’all, the very next day, I started to gain it back.”

    Winfrey called obesity “a disease, not a character flaw.”

    “In my lifetime, I never dreamed we would be talking about medicines that would be providing hope to people like me,” Winfrey championed.


    Breaking news from Canada and around the world
    sent to your email, as it happens.


    Breaking news from Canada and around the world
    sent to your email, as it happens.

    She said the medications, as well as causing her to lose weight, helped Winfrey “no longer blame” herself for her body fluctuations.

    “When I tell you how many times I have blamed myself because you think, ‘I’m smart enough to figure this out,’ and then to hear all along it’s you fighting your brain!” Winfrey said of weight loss.

    She said the medication has helped her stop “constantly thinking about what the next meal is going to be.”

    Story continues below advertisement

    Winfrey added she also hikes three to five miles (about five to eight kilometres) every day, while regularly running and eating a heathy diet to maintain her slim figure.

    The TV special featured several interviews with medical professionals about weight-loss medications. Patients who, like Winfrey, have utilized these drugs to combat obesity were interviewed as well. Many of the users spoke highly of the medications, though some users also expressed critical opinions.

    Still, Winfrey noted weight-loss drugs may not be for everyone.

    “For people who feel happy and healthy in celebrating life in a bigger body and don’t want the medications, I say: ‘Bless you,’” Oprah signed off at the hour’s end. “And for all the people who believe diet and exercise is the best and only way to lose excess weight, bless you too if that works for you.”

    An Oprah Special: Shame, Blame, and the Weight Loss Revolution aired only weeks after Winfrey announced she will leave her role on the WeightWatchers board of directors. Winfrey, who had been one of the company’s most prevalent spokespersons, decided not to stand for board re-election after she publicly revealed she was taking an unnamed weight-loss medication.

    Winfrey donated her shares in the company to the Smithsonian Museum of African American History and Culture in Washington, D.C.

    In December 2023, Winfrey told People magazine she was using a weight-loss drug as a “maintenance tool” for her fluctuating weight. The disclosure came after Winfrey’s social media followers speculated that the star may be taking Ozempic or another similar medication.

    Story continues below advertisement

    Winfrey said she uses weight-loss drugs “as a tool to manage not yo-yoing.”

    Due to popular demand, the manufacturers of several drugs, including Ozempic, have experienced shortages that have continued into 2024. The shortages have affected many Canadian patients with Type 2 diabetes, who treat the condition with drugs like Ozempic. Some diabetics who had been using Ozempic have since been forced to change their medications.


    Click to play video: 'Ozempic shortage impact on Canadian patients with Type 2 diabetes'


    Ozempic shortage impact on Canadian patients with Type 2 diabetes


     

    Story continues below advertisement

    &copy 2024 Global News, a division of Corus Entertainment Inc.

    [ad_2]

    Sarah Do Couto

    Source link

  • FDA warns about Ozempic counterfeits, seizes thousands of fake drugs

    FDA warns about Ozempic counterfeits, seizes thousands of fake drugs

    [ad_1]

    Poison centers see spike weight-loss drug calls


    U.S. poison centers see spike in calls over weight-loss drugs

    00:35

    Federal officials are urging Ozempic users to check the legitimacy of their medications because of counterfeit versions of the popular diabetes drug that have been sold through legitimate sources. 

    The Food and Drug Administration has seized “thousands of units” of counterfeit Ozempic 1 milligram injections in an investigation that is ongoing, it said Thursday in a consumer alert. The drugs have been linked to five reports of illness, but none of the cases were serious, the notice shows.

    screenshot-2023-12-22-at-1-38-18-pm.png
    Counterfeit Ozempic drugs are identifiable by the numbers on their cartons. 

    U.S. Food and Drug Administration


    Ozempic products with lot number NAR0074 and serial number 430834149057 on the box are counterfeit products and should not be used, the FDA warned.

    The bogus drugs’ ingredients, quality and safety are not yet known, the FDA said. Ozempic-maker Novo Nordisk and the FDA are testing the seized products, according to the notice. 

    The illegitimate products come with pen labels, cartons, fact sheets and needles that are also counterfeit, the notice shows. The needles pose an infection risk to consumers because it remains unclear whether or not they are sterile, Novo Nordisk said Thursday in a statement. 

    Ozempic has been in short supply this year as celebrities touted the drug’s slimming side effects, fueling public interest in the product.

    Amid the shortages, fraudsters have sold illegitimate Ozempic-like products to pharmacies, masquerading as medical wholesaler employees. It remains unclear whether the fakes are authentic products that are being diverted from foreign markets or whether they are being produced by scammers within the U.S.

    The FDA last month revealed three people had been hospitalized after taking suspected counterfeit products containing semaglutide, the active ingredient in Ozempic. 

    The FDA is advising retail pharmacies to buy authentic Ozempic only through authorized distributors and for patients to get it only through state-licensed pharmacies. 

    Consumers can report suspect Ozempic packages by calling 800-332-1088 or by contacting a state complaint coordinator.

    The Associated Press contributed reporting. 

    [ad_2]

    Source link

  • Ozempic overdose? Poison control experts explain why thousands OD'd this year

    Ozempic overdose? Poison control experts explain why thousands OD'd this year

    [ad_1]

    Some of those taking Ozempic or Wegovy are learning that too much of a good thing is never good.

    Semaglutide, the medication prescribed under the brand names Ozempic, for treating Type 2 diabetes, and Wegovy, for weight management, works by mimicking the hormone GLP-1, which is released by the gut after eating. The hormone has several effects in the body, such as stimulating insulin production, slowing gastric emptying and lowering blood sugar.

    It has been hailed for its weight-loss benefits, most conspicuously among celebrities. Oprah Winfrey recently said she uses weight-loss medication and lauded “the fact that there’s a medically approved prescription for managing weight and staying healthier, in my lifetime.” She said it felt “like a gift.”

    But between Jan. 1 and Nov. 30 this year, at least 2,941 Americans reported overdose exposures to semaglutide, according to a recent report from America’s Poison Centers, a national nonprofit representing 55 poison centers in the United States.

    California accounted for about 350 of the reports, or around 12%, according to Raymond Ho, the managing director of the California Poison Control System. Ho said the number roughly corresponds to the proportion of California’s population to the rest of the country.

    The nationwide number of semaglutide overdoses this year is more than double the 1,447 reported in 2022, which was more than double the 607 semaglutide overdoses reported in 2021.

    There were only 364 reported semaglutide overdoses in 2020 and 196 in 2019, less than 10% of the number that occurred so far this year.

    America’s Poison Centers released the data with a disclaimer that the figures likely represent an undercount in the number of cases involving semaglutide, as the center only included those voluntarily reported to poison control centers.

    “It is an alarming trend from a poison center perspective,” Ho said. “We get the usual dosing error calls, and all of a sudden there’s an explosion of people calling much more regularly about this.”

    The use of semaglutide and other GLP-1 imitators has surged in popularity over the last year as a quick and effective way to manage weight loss. More than 4 million prescriptions for semaglutide were issued in the United States in 2020, according to federal data, and usage of the drug has continued to grow since then.

    Dr. Stephen Petrou, an emergency medicine physician and toxicology fellow with California Poison Control, said there were multiple factors contributing to the increase in overdoses.

    “Not only is there rising social popularity” of the drug, Petrou said, “but there’s also wider FDA indications for use.”

    Semaglutide was patented by the Danish pharmaceutical company Novo Nordisk in 2012 and has been available in the United States since the FDA approved it in 2017. The drug was originally released as Ozempic for Type 2 diabetics to manage blood sugar levels. Moderate weight loss was found to be a common side effect of the drug, and the FDA approved a different formulation of semaglutide, called Wegovy, for that purpose in 2021.

    Ho and Petrou said the different formulations of semaglutide could help explain why it has led to so many more overdoses than other drugs of its class. Both are administered via weekly injections, with Wegovy in single-use pens and Ozempic in needles that can vary in dosage. Standard dosages range from 0.25 mg to 2.4 mg for weekly injections, depending on the prescription.

    “Someone who is unable to get Wegovy can resort to using Ozempic instead, because it is the same medication, but they may start to [adjust] their dose” upward, Petrou said. “That’s when they might encounter problems.”

    Ho and Petrou said the vast majority of semaglutide overdose reports are accidental, either due to patients not waiting a week between doses or by misunderstanding dosing instructions. Unlike the GLP-1 hormone, which is rapidly metabolized by the body, semaglutide and similar medications have much longer half-lives, meaning the medication can build up inside the body if not enough time elapses between doses.

    Furthermore, semaglutide can also be taken orally as a daily pill — sold under the name Rybelsus — but overdoses are rarely reported.

    “We’re not seeing cases of mis-administration or toxicity or overdose with that medication,” Petrou said.

    Ho and Petrou explained the signs of semaglutide overdose can resemble those of hypoglycemia, also known as low blood sugar. Symptoms can begin with increased heart rate, sweating, dizziness and irritability. More serious cases can cause confusion, delirium and coma.

    “If they have hypoglycemia, the good majority of them will have to be admitted to the hospital and monitored and watched closely, because of how long these drugs last,” Ho said.

    Ho encourages everyone who is prescribed semaglutide to thoroughly read the medication’s label and follow the dosing instructions listed.

    “We always say this: The dose makes the poison,” Ho said.

    Anyone who needs emergency poison assistance or has other poisoning-related inquiries can call the national Poison Helpline at (800) 222-1222 or visit the Poison Help website.

    [ad_2]

    Jeremy Childs

    Source link

  • WeightWatchers launches program for users of Ozempic and other weight-loss drugs

    WeightWatchers launches program for users of Ozempic and other weight-loss drugs

    [ad_1]

    WeightWatchers has started a new chapter as the 60-year company looks to tap the fast-growing market for people using prescription weight-loss drugs.

    The diet company this week launched WeightWatchers GLP-1, a subscription program focused on the health and nutrition needs of patients using Ozempic and Wegovy, two brands of semaglutide, a diabetes drug that has exploded in popularity for its effectiveness in helping people lose weight. 

    With its new membership offering, WeightWatchers is hoping to stay relevant in a rapidly changing industry. Widespread use of Ozempic and Wegovy has upended the diet industry and even changed consumer eating habits. An estimated 24 million people, or 7% of the U.S. population, could be using the drugs by 2035, according to a report by Morgan Stanley Research.

    “The WeightWatchers GLP-1 Program helps members establish and adhere to healthy habits while the food noise from GLP-1 medications is reduced,” Gary Foster, chief scientific officer at WeightWatchers, said in a statement announcing the program.

    GLP-1 refers to a gut hormone that is key to how semaglutide works with the brain to suppress appetite. While Ozempic and Wegovy are both brandname equivalents of semaglutide, only Wegovy is approved by the Food and Drug Administration for chronic weight management. Yet off-label use of Ozempic is common among those who lack insurance coverage for Wegovy.


    Weight loss drug Wegovy cut risk of serious heart problems by 20%, study finds

    03:18

    “A large portion of people do not have insurance coverage for weight-management medications, but they might for Ozempic,” said Kimberly Gudzune, M.D., in an article on WeightWatchers’ website.

    The program, developed by a team of scientists, dietitians, fitness experts and others specializing in obesity, is designed to help members use the new anti-obesity medications, which can lead to rapid changes in weight. Offerings include daily nutrition and activity targets, including weight training to help subscribers maintain muscle mass as they shed pounds. 

    “What we’ve seen is that people taking GLP-1 medications need help with a different set of behavioral challenges in comparison to people not on these medications,” Foster said. “In the context of a reduced appetite, large weight losses, and a significant loss in muscle, it is important to help people focus on dietary protein and activity to minimize the loss of muscle mass.”

    [ad_2]

    Source link

  • Oprah Winfrey opens up about using weight-loss medication:

    Oprah Winfrey opens up about using weight-loss medication:

    [ad_1]

    Oprah Winfrey has revealed that she has recently turned to a weight-loss medication after years of struggling with her weight.

    In an interview with People magazine, the former talk show host recalled the public ridicule she endured for decades about her size and how she internalized the criticism. 

    “It was public sport to make fun of me for 25 years,” Winfrey told People.”I have been blamed and shamed, and I blamed and shamed myself.”

    She mentioned a particularly harsh instance where a magazine cover dubbed her “Dumpy, Frumpy and Downright Lumpy.”

    “I didn’t feel angry,” she told People. “I felt sad. I felt hurt. I swallowed the shame. I accepted that it was my fault.”

    Winfrey’s weight fluctuation has been well documented, but things began to improve for her health during rehabilitation after a knee surgery in 2021. 

    She said she began hiking and focusing on her fitness, making strides. 

    “I felt stronger, more fit, and more alive than I’d felt in years,” she told People. 

    Winfrey said she recommended medications for weight loss for others for years but didn’t consider them for herself until she taped a panel conversation with weight loss experts and clinicians as part of “Oprah Daily’s Life You Want” series, which aired in September. 

    During the panel she said that the weight-loss drug Ozempic was “the easy way out,” but she said she had an epiphany as she spoke to the panelist. 

    “I had the biggest ‘aha’ along with many people in that audience,” Winfrey told People. “I realized I’d been blaming myself all these years for being overweight, and I have a predisposition that no amount of willpower is going to control.”

    “Obesity is a disease. It’s not about willpower —it’s about the brain,” she added. 

    Winfrey said she changed her mindset about weight-loss medication and got a prescription; she does not name the medication in the interview.

    However, Winfrey stressed that she has to work hard to maintain her weight loss, but she still sees the medication as a “gift.”

    “The fact that there’s a medically approved prescription for managing weight and staying healthier, in my lifetime, feels like relief, like redemption, like a gift, and not something to hide behind and once again be ridiculed for. I’m done with the shaming from other people and particularly myself.”

    Over the last year, there has been a high demand for semaglutide, the generic form of brand name drugs Ozempic, Wegovy and Rybelsus. 

    These drugs cause weight loss and have been known to be highly effective: One doctor told CBS News the drugs can help people lose about 15% of their body weight –considerably more than previous generations of weight loss drugs.

    Semaglutide drugs work by imitating a gut hormone called GLP1, or glucagon-like peptide hormone, that “makes that gut hormone work better to enhance communication between the gut and the brain and make us feel fuller and also help with reducing appetite,” said Dr. Amanda Velazquez, who works at Cedars-Sinai Center for Weight Management and Metabolic Health in Los Angeles. 

    Ozempic and other drugs like it were originally developed to treat patients with diabetes as they produce insulin and lower blood sugar. They can produce serious side effects, and doctors warn that long-term impacts remain unknown.

    [ad_2]

    Source link

  • CBD, Intermittent Fasting And Weight Loss

    CBD, Intermittent Fasting And Weight Loss

    [ad_1]

    Some people struggle with weight loss and are looking for a silver bullet.  Currently, the trend is Ozempic®.  The tradition way eating less and moving more is the best, for for some, they need additional help. Intermittent fasting is an eating plan which switches between fasting and eating on a regular schedule. Research shows intermittent fasting is a way for some to manage weight.

    RELATED: Marijuana For A Lean Physique? Science Weighs In

    Before diving into the reasons why CBD’s capabilities might make for better fasts and might help manage people’s hunger, it’s important to understand what the fasting process is about and why it’s been so embraced as of late. 

    We’ll focus on the most popular and common methods: the 18/6, 16/8, and Eat-Stop-Eat. In the first method, 18 represents the hours spent fasting, and 6 represents your eating window. By following the 18/6 you’ll spend 18 hours fasting and have a window of 6 hours to get your necessary calories. The 16/8 is the same thing, with slightly different windows for each. For some people, this method works perfectly since all they have to do is avoid snacks past their bedtime and either skip breakfast or eat it later in the morning. 

    For those who are stronger willed, there’s the Eat-Stop-Eat method, which is a little more extreme, increasing the amount of time you spend fasting and the amount of time you have to eat. People can spend 24 hours without eating, only ingesting liquids without calories, like coffee and tea, and then have a day to eat with no limitations. Then they get back to fasting and so on and so forth. This method produces more effective intermittent fasting results, preserving lean muscle mass, promoting hormone levels and cutting calories. 

    Intermittent fasting is built upon the knowledge once the body spends over 16 hours without eating, it automatically begins to break down fat as a replacement for glucose. This is a process called ketosis. Aside from burning fat, ketosis also makes your body work harder to repair damaged DNA and replace old cells, some of which have been correlated with Alzheimer’s disease. There’s a lot of promise for fasting and a lot of good stuff associated with it. 

    CBD may enhance the fasting process by reducing your appetite, contributing with hormone regulation, fighting inflammation and even preventing diabetes. While THC is known for increasing people’s hunger, CBD doesn’t share these same capabilities. Most of the time, people eat when they’re bored or anxious; CBD makes for a good option for these types of people, keeping their brains focused and relaxed and preventing snacking. 

    RELATED: Federal Study Aims To Learn More About Marijuana And Weight Loss

    CBD also boosts the health capabilities of fasting, producing larger and more impacting results. CBD can be consumed as oils, topicals or capsules while fasting – as long as these don’t have calories – or as edibles once people have broken their fasts. 

    While there’s no studies proving CBD oil makes for better fasts, the evidence exists suggesting it might help people who have a hard time wrapping their heads around such a long period of time spent without eating. In any case, it sounds like a good supplement if you’re looking to give intermittent fasting a shot.

    [ad_2]

    Amy Hansen

    Source link

  • FDA approves a new weight loss drug, Zepbound from Eli Lilly

    FDA approves a new weight loss drug, Zepbound from Eli Lilly

    [ad_1]

    The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well.

    While Mounjaro had already been used by some patients “off-label” for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too.

    Zepbound will be available for patients in the U.S. by the end of the year, the drugmaker said.

    The company said Wednesday in a news release that the medication will be sold at a cheaper list price than its semaglutide competitors from Novo Nordisk, which are branded as Wegovy for weight loss and Ozempic for diabetes. 

    “New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management,” Joe Nadglowski, CEO of the Obesity Action Coalition, said in Eli Lilly’s release. The group receives funding from Eli Lilly and other pharmaceutical and health care companies.

    The FDA’s approval of Zepbound was partially based on a trial of adults without diabetes, which found that participants — who averaged 231 pounds at the start of the trial — who were given the highest approved dose lost around 18% of their body weight compared to placebo.

    “In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need,” the FDA’s Dr. John Sharretts, director of the agency’s Division of Diabetes, Lipid Disorders, and Obesity, said in a news release.

    While there have not been results from large clinical trials comparing Novo Nordisk’s and Eli Lilly’s medications head-to-head, there is some research to suggest Zepboud could outperform Ozempic

    A meta-analysis presented at the annual meeting of the European Association for the Study of Diabetes in October concluded tirzepatide was “more effective for weight loss than semaglutide, with a larger weight-loss effect at higher doses,” but acknowledged limitations in trying to make a direct comparisons of the two.

    In a report earlier this year comparing semaglutide and tirzepatide for diabetics, the Institute for Clinical and Economic Review concluded that tirzepatide showed “greater reduction” in weight and other key markers, but “had a greater incidence of gastrointestinal side effects, severe adverse events, and discontinuation compared with semaglutide.”

    Zepbound carries the risk of an array of potential side effects, the FDA says, including nausea, diarrhea, vomiting, constipation, and hair loss. 

    Like with other weight loss drugs in this class, some of Zepbound’s side effects could be serious.  

    People with a history of severe gastroparesis, or stomach paralysis, should not use the drug, the FDA says. 

    Eli Lilly and Novo Nordisk have both faced claims that their drugs can cause stomach paralysis. The FDA recently moved to acknowledge reports of ileus, or a blockage in the intestines, on Ozempic’s label.

    The agency also notes that other people could be at higher risk of more severe issues from Zepbound, including patients with a history of medullary thyroid cancer, pancreas inflammation, or severe gastrointestinal disease.

    It also should not be combined with other so-called GLP-1 receptor agonist drugs, which include its sibling Mounjaro, as well as Wegovy and Ozempic. 

    “The safety and effectiveness of coadministration of Zepbound with other medications for weight management have not been established,” the agency says.

    [ad_2]

    Source link

  • Weight loss drugs could have economic side effect

    Weight loss drugs could have economic side effect

    [ad_1]

    Weight loss drugs could have economic side effect – CBS News


    Watch CBS News



    Weight loss drugs could have economic side effect, experts say

    Be the first to know

    Get browser notifications for breaking news, live events, and exclusive reporting.


    [ad_2]

    Source link

  • FDA updates Ozempic label with potential blocked intestines side effect, also reported with Wegovy and Mounjaro

    FDA updates Ozempic label with potential blocked intestines side effect, also reported with Wegovy and Mounjaro

    [ad_1]

    Weight-loss drugs can have side effects


    Health officials raise concern about weight-loss drugs’ possible side effects

    05:19

    The label for the diabetes drug Ozempic — which has become popular for weight loss — now acknowledges reports of blocked intestines following use of the medication. The change comes after the Food and Drug Administration greenlighted a series of updates from drugmaker Novo Nordisk for its product. 

    Ozempic now joins other products in this booming class of so-called GLP-1 agonist medications which acknowledge increased reports of what doctos call ileus, or a blockage in the intestines. 

    Weight loss drug Wegovy, which is also an injection of semaglutide manufactured by Novo Nordisk, acknowledges reports of ileus on its label as well, as does Mounjaro, a diabetes medication from Eli Lilly.

    However, the FDA stopped short of directly blaming the potentially life-threatening condition on the drug.

    “Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure,” the label reads.

    The FDA has received 8,571 reports of gastrointestinal disorders after use of semaglutide medications, which includes both Ozempic and Wegovy, according to data published by the regulator through June 30. 

    Ileus is specifically mentioned as a reaction in 33 cases listed on the FDA’s dashboard of people taking semaglutide, including two deaths. 

    Both Novo Nordisk and Eli Lilly are facing a lawsuit over claims that the medications can cause a similar condition called gastroparesis, or paralysis of the stomach, which stops food from reaching the small intestine despite there being no blockage.

    Spokespeople for Novo Nordisk and the FDA did not immediately respond to a request for comment.

    [ad_2]

    Source link

  • Ozempic and other weight-loss drugs boost pharmacy sales at Rite Aid

    Ozempic and other weight-loss drugs boost pharmacy sales at Rite Aid

    [ad_1]

    Rite Aid Corp. said Thursday that its fiscal first-quarter pharmacy sales got a boost from a new class of drug.

    Pharmacy sales, which rose 3.4% from a year ago, were boosted by higher sales of Ozempic and other GLP-1 receptor agonists, which are used to treat Type 2 diabetes and obesity.

    The higher sales did not translate into profit, however.

    “As the cost of these drugs is also high, the impact of the increase in volume of these drugs on our gross profit dollars is minimal,” Rite Aid Chief Financial Officer Matthew Schroeder told analysts on the company’s earnings call, according to a FactSet transcript.

    Still, the company
    RAD,
    +2.96%

    cheered investors by raising its full-year revenue guidance due to the sales bump from Ozempic and other high-dollar GLP-1 drugs. It now expects revenue of $22.6 billion to $23 billion, ahead of the FactSet consensus of $22.3 billion.

    Ozempic, Wegovy and Rybelsus, which are made by Novo Nordisk
    NOVO.B,
    +0.17%

    NOVO.B,
    +0.17%
    ,
    and Mounjaro, which is made by Eli Lilly & Co.
    LLY,
    +1.34%
    ,
    have become so popular in the U.S. that supplies have at times run short and the U.S. Food and Drug Administration has been forced to warn patients against using knockoff versions.

    The drugs are administered by injection and mimic the effects of GLP-1, a gut hormone that can help control blood-sugar levels and reduce appetite. GLP stands for glucagon-like peptide.

    Ozempic, Rybelsus and Mounjaro have been approved by the Food and Drug Administration for treatment of Type 2 diabetes, while Wegovy is approved for people with obesity and for certain people with excess weight combined with weight-related medical problems. 

    Last year, more than 5 million prescriptions for Ozempic, Mounjaro, Rybelsus or Wegovy were written for weight management, up from 230,000 in 2019, according to data and analytics firm Komodo Health.

    Obesity drugs could be a $54 billion market by 2030, up from $2.4 billion in 2022, Morgan Stanley said in a report last year. Reports of people who take GLP-1 drugs seeing improvements in addictive behaviors such as smoking and drinking have lately amplified interest in the medications.  

    For more, read: The dark side of the weight-loss-drug craze: eating disorders, medication shortages, dangerous knockoffs

    Drug companies, including Lilly and Pfizer Inc.
    PFE,
    -0.32%
    ,
    are now working to develop treatments in the form of pills that could be more convenient alternatives to the injectables.

    See now: Weight-loss drugs in development aim to replace injections with pills

    Rite Aid’s overall numbers surprised on the upside, as its loss was narrower than expected and revenue beat the consensus estimate.

    For more, see: Rite Aid’s stock soars 7.5% after company surprises with earnings that are less bad than feared

    Eleanor Laise contributed.

    [ad_2]

    Source link

  • The Oscars 2023: The Good, The Bad, And The Ugly

    The Oscars 2023: The Good, The Bad, And The Ugly

    [ad_1]

    Whenever I watch an awards ceremony for the “biggest names in Hollywood,” I regret tuning in about 30 minutes in. It sounds like a great idea to watch
    The Oscars in theory, but in practice, it’s more agonizing than a low-scoring football game. Last night’s 95th Annual Academy Awards hosted by Jimmy Kimmel held us hostage and threatened to go on for almost four hours.


    This year, we were faced with the cold, hard truth: every celeb we know and love is on Ozempic. And Nicole Kidman will forever give us a meme even if she doesn’t speak.

    The Winners

    The worst part about these award shows is that you know who’s going to win.
    Everything, Everywhere, All At Once was going for a sweep of their 11 Oscar nominations, so why do I have to watch everyone, everywhere, all at once make a five minute speech? Seems borderline criminal.

    The first award of the night was given to Best Supporting Actress, with
    EEAO having two nominees in Jamie Lee Curtis and Stephanie Hsu, alongside a roster of talent in Angela Bassett (Black Panther: Wakanda Forever) and Kerry Condon (The Banshees of Inisherin). Controversially, or maybe not, Jamie Lee won.

    A24’s multiverse
    EEAO became the most awarded filem of all time, winning Best Picture, Best Director, and Best Leading Actress with Michelle Yeoh becoming the first Asian actress to win. I was on the edge of my seat for one of the closer races of the night, Best Leading Actor. With names like Austin Butler (Elvis), Brendan Fraser (The Whale), Colin Farrell (Banshees), Paul Mescal (Aftersun), and Bill Nighy (Living), Fraser ended up taking home the Best Leading Actor award.

    Believe me, between Ke Huy Quan and Brendan Fraser’s speeches, not a dry eye was in the house.

    The Drama

    It wouldn’t be
    The Oscars without drama. So let’s dig in. Starting with the red carpet – which was actually champagne colored and very ugly this year – we had Vanessa Hudgens and Ashley Graham doing interviews. There was a very clear opportunity for millions of TikTok clips if you would have let Baby V interview ex-boyfriend and permanent Elvis stand-in, Austin Butler, but no. Of course not.

    Ashley Graham instead interviewed Hugh Grant for quite possibly the most awkward interview of all time. Hugh Grant all but refused to answer questions, even calling
    The Oscars “Vanity Fair,” to which Graham responds “Vanity Fair is where you’ll be letting loose later.” The whole thing made me sick to my stomach.

    And does anyone else feel bad that we keep inviting Rihanna to perform “Lift Me Up” at these shows and then she doesn’t win the award? I think adding her and A$AP Rocky to the audience brings added style and attractiveness that would otherwise lack without them – so maybe give her an award to keep her coming back?

    We also have Jamie Lee Curtis’s controversial win as one of the only white women nominated in her category. And while I agree Angela Bassett
    did the thing both in her performance in Black Panther and her outfit last night, it’s hard to get mad at an actress for winning an award the Academy designated for her. Blame The Academy, not the women.

    This year’s major cringe wasn’t a slap, but rather Jimmy Kimmel asking activist Malala Yousafzai if she thought Harry Styles really spit on Chris Pine. After she proceeds to say she only talks about peace, Kimmel nicknamed her Malala-land. Again, just gauge my eyes out at this point.

    And for those wondering about hookups, Bad Bunny and Kendall Jenner were seen together at Jay-Z and Beyonce’s afterparty. Also in attendance? Gigi Hadid and Leonardo DiCaprio. Do with that information what you will.

    The Style

    Perhaps my favorite part of the night: the clothes. Some of my favorite looks of the night were as follows:

    Hunter Schafer

    Hunter Schafer

    Anthony Harvey/Shutterstock

    Megan Thee Stallion

    Megan Thee Stallion

    Megan Thee Stallion


    Matt Baron/BEI/Shutterstock

    Rihanna

    Rihanna

    Rihanna

    Rob Latour/Shutterstock

    Lady Gaga

    Lady Gaga

    Lady Gaga

    Chelsea Lauren/Shutterstock

    Angela Bassett

    Angela Bassett

    Angela Bassett

    Chelsea Lauren/Shutterstock

    Tems

    Tems

    Tems

    Chelsea Lauren/Shutterstock

    [ad_2]

    Jai Phillips

    Source link

  • 80% With Diabetes Eligible for New Drugs, but Cost Is a Barrier

    80% With Diabetes Eligible for New Drugs, but Cost Is a Barrier

    [ad_1]

    March 6, 2023 — More than 80% of U.S. adults with type 2 diabetes meet the criteria to use new treatment drugs, such as semaglutide, which is marketed as Ozempic, according to a new study published in the Annals of Internal Medicine.

    However, only about 1 in 10 of those who meet the criteria used the drugs in recent years, the study found. In addition, the high prices for some of the drugs means they may put them out of reach as the first drug treatment for these patients. Most people with type 2 diabetes are prescribed metformin initially, but generally have other medications added on, but some of the newer drugs are now recommended as first-line treatment for some. 

    “It’s critical that we continue to study the best ways to manage type 2 diabetes (including medications and lifestyle changes), but it’s also important to examine how available these methods are to people,” says lead author Shichao Tang, PhD, a researcher with the Division of Diabetes Translation at the CDC’s National Center for Chronic Disease Prevention.

    “This includes researching how many people are using certain tools or medications and how many people are eligible for them, which was the aim of this study,” Tang says. 

    A 2022 report from the American Diabetes Association and European Association for the Study of Diabetes recommended the use of certain drugs, such as Ozempic, which is given as a weekly injection, with other similar drugs available as daily injections, and oral tablets, for patients with type 2 diabetes. 

    This is because, as well as lowering blood sugar, these new drugs have been found to reduce the risks of complications of diabetes, such as heart disease and kidney disease, and they also result in weight loss, compared with older drugs. 

    The researchers estimated that, for the 22.4 million U.S. adults with diagnosed type 2 diabetes, about 82.3% would meet the recommended criteria to use drugs from these two new classes. About 94.5% of Medicare recipients with type 2 would be recommended to use them as well.

    However, only 3.7% of those who met the criteria used them during the study period and just 5.3% of those eligible for the oral tablets used them. 

    About 9.1% used either of them before the most recent 2022 guidelines, which opened up the medications as first-line treatment for patients with type 2 diabetes.

    Based on retail prices listed on a US-based website, a 30-day supply of an oral tablet drug can cost about $550-$600/month, while common injected drugs can run from a few hundred dollars for a daily injection or close to $1,000 for a version given weekly.

    Prior studies suggest that the two drug types could be cost-effective as second-line treatments, the authors note. However, the current costs would need to drop by 70% for them to be cost-effective as first-line treatments. 

    Additional studies are needed to understand if the new treatments are cost-effective for certain patient subgroups as first-line medications.

    [ad_2]

    Source link

  • The Ozempic Discourse is Bad, Boring, and Blatantly Fatphobic

    The Ozempic Discourse is Bad, Boring, and Blatantly Fatphobic

    [ad_1]

    For all young, hip, city folk of a certain age, The Cut is an online Bible. My conversations regularly feature exhaustive discussions about their most recent articles. And when I scroll through all my friends’ Instagram, I see the “Liked By” tab. It’s like waving hello, over Instagram. And if I notice that a friend’s name is missing, I shoot over the most recent meme or headline in a DM. It’s friend homework. Catching up on The Cut.

    And, as a writer, I’m convinced that The Cut and the rest of New York Magazine sit at the center of the zeitgeist. For our jobs, we need to know what the culture is saying. And The Cut speaks for the culture.

    This is why it was so alarming when, on February 27th, they posted another piece adding to the Ozempic discourse. This rumination on the Hollywood-touted appetite suppressant — and literally a diabetes medication — was titled: “Life After Food.” And in the opening paragraphs, an interviewee is quoted saying: “We don’t talk about it, but everybody knows it. Thin is power.”

    Besties, when I say my jaw is on the floor, I am not lying. But I soldiered on. I kept reading. Where are they going with this? I wondered. Surely, somewhere less bleak than this. Unfortunately, I was disappointed.


    “Weren’t we supposed to have moved on from this? The discourse on bodies has changed since the days when a slender figure could be blithely and uncomplicatedly celebrated, sought, or advertised,” the article poses. “Ours was supposed to be the feel-good era of Lizzo and Ashley Graham and Adele.”

    And while this moment in the piece gave me hope, it was quickly lost. Their argument is essentially this: now that Hollywood has abandoned the idea of body positivity, it’s totally fine if we do, too.

    Many of the consequent behaviors and results of this drug sound exactly like disordered eating symptoms. The thinspo blogs in indie-sleaze era Tumblr would have had a field day with this. It’s literally triggering to read. And yet, laid all out there with a cynical snark that never admonishes this behavior, but rather declares it as the state of the union.

    Mind you, this is just weeks after The Cut published an essay by plus-sized influencer Remi Bader about the industry using her as a prop while she struggled with an eating disorder.

    Bader told the Not Skinny but Not Fat Podcast about her own Ozempic experience. “They said I need this. And I had a lot of mixed feelings,” she said. “A few months later I went off it and got into the bad bingeing.”

    The call is coming from inside the house.

    And this isn’t just a problem with this specific piece. This is an attitude being blasted all over the internet. The jig is up! The joke is over! Thin is in again — no matter the cost.

    From the perspective of those gatekeeping industries like Hollywood and the fashion world — which have become increasingly enmeshed — body positivity is no longer on anyone’s mind.

    By BOF’s count, there were noticeably fewer plus-size models cast in runway shows at New York Fashion Week this season. And more distressing than the meager number of curve models strutting down the runway this fashion week was the styles that emerged as dominant.

    The rise of Y2K fashion trends is bringing back that era’s devastating beauty criteria. High-waisted pants have been traded for lower waists, micro tops, and sheer fabrics that put the body on display. Even skinny jeans are making a comeback! Instead of designers adopting these trends for all body types — celebrating how various bodies look in figure-skimming clothes — they have regressed to the rail-thin standard of yore.

    It’s Bella Hadid’s teeny, tiny frame at Coperni. It’s the red carpet obsession with naked dresses. It’s the goddamn Miu Miu skirt. I mean, we called it: the Miu Miu skirt launched the apocalypse.

    Remember when that mini-skirt set — and those fast fashion knockoffs — were all over your feed? But you never saw anyone wear it in real life? That’s not just because it’s a completely impractical piece of clothing. It’s because Miu Miu never made accessible sizes for anyone other than — you guessed it — sample-sized models and celebrities.

    Yet, this viral status symbol never captured the public’s attention. People weren’t clamoring outside Miu Miu stores to buy this. But the images proliferated everywhere. Why? Because it glorified an idea — one of impractical whimsy, but also of emaciation.

    And now the Miu Miu skirt is joined by the Ozempic craze as the horsemen of the apocalypse, signaling the nail in the coffin for body diversity and a return to thin-obsessed pop culture.

    Let’s be clear: thinness was never really out. Fatfobia still runs rampant through our society. But we’re not even pretending anymore.

    This discourse has gone the way the plastic surgery discourse went. Rather than empowering people to celebrate their natural features and reject the homogenous standards of beauty we’re constantly exposed to, we’ve shrugged our shoulders.

    There’s no shame in having insecurities. But I think we’ve lost the plot. We’re throwing our hands up and normalizing an insane appetite suppressant and moralizing it because the people who are taking it imagine they’ve unlocked some secret?

    “Especially for women who have been thin their whole lives — but not skinny, not fashion thin — the idea of touching that without having to sweat is really fun,” says one of The Cut’s sources. “It’s really fun for them to have their jeans hang off of them like they’re a Hadid. There is an addictive quality to it.”

    This addictive quality described is the product of a body hierarchy that places thin people at the top and fat people at the bottom. This same hierarchy also prioritizes whiteness, and conforming to European standards of beauty. So, why are we so obsessed with it?

    I, for one, refuse to treat this like it’s yet another trend to get in line with. Bigger bodies should not be treated like they’re disposable for the trend cycle. We definitely shouldn’t normalize starving ourselves.

    But, luckily, there is hope. Florence Pugh and other leading ladies have talked about their refusal to diet for roles. Models like Paloma Elsesser are preaching radical self-acceptance. And we can’t overstate the impact of megastars like Rihanna and Selena Gomez casually addressing their weight gain and loudly loving themselves as their bodies pass through many natural phases.

    These efforts are bolstered by brands that extend their sizing, making space for the big girls in a world that wants them to disappear. But we now have terrific, plus-sized brands that are creating stylish, trend-forward apparel in the face of so much blatant fatphobia.

    Here are some of the most inclusive spectacular brands we’re loving right now:


    All products featured are independently selected by our editors. Things you buy through our links may earn us a commission

    [ad_2]

    LKC

    Source link

  • Dieters Who Use Scarce Diabetes Drug Ozempic Could Face Side Effects

    Dieters Who Use Scarce Diabetes Drug Ozempic Could Face Side Effects

    [ad_1]

    By Dennis Thompson 

    HealthDay Reporter

    WEDNESDAY, Feb. 1, 2023 (HealthDay News) — Mila Clarke started taking Ozempic in 2020 to help manage her diabetes, but was pleasantly surprised to find herself soon shedding pounds.

    “I was like, this is really weird because I’m not having to try very hard to do this,” said Clarke, who has been diagnosed with both type 1 and type 2 diabetes and chronicles her diabetes journey on her Hangry Woman blog. “And as I kept going on, I kept noticing that the weight was falling off.”

    Then the side effects started — most worryingly, a racing and palpitating heartbeat.

    “I could be laying down in bed and my heart rate, like resting heart rate, would be 120 beats per minute,” the sort of rate associated with exercise, Clarke said in an interview with HealthDay Now. “It was really having an effect on my heart rate, and that was really terrifying.”

    First approved to treat diabetes under the brand name Ozempic, the drug semaglutide received federal approval in June 2021 to also be prescribed as a weight-loss medication — with the brand name Wegovy.

    People interested in dropping pounds — either for their health or for vanity’s sake — flooded the market for semaglutide, making it difficult to impossible for people with diabetes to fill prescriptions needed to manage their condition.

    But semaglutide comes with some troubling side effects that people might not have considered in their search for the perfect body, experts say.

    These can range from nausea and vomiting to premature aging of the face, as well as heart problems.

    The drug is a synthetic form of a naturally occurring gut hormone, Dr. Holly Lofton, an obesity medicine specialist with NYU Langone Health in New York City, told HealthDay Now.

    “It goes to different areas of the brain and blocks hunger signals, it goes to your stomach and slows down the rate your stomach empties, and it hormonally helps your body be more sensitive to the insulin that you produce, thus helping your fat cells shrink,” Lofton explained.

    Because of the way it works, semaglutide’s most commonly reported side effects involve the gastrointestinal system, Lofton said.

    Those were the first that Clarke experienced.

    Scary side effects, like a racing heartbeat

    “You start out on a very low dose to have your body get used to it,” Clarke said. “You can get a lot of nausea, diarrhea, you can feel dizzy.”

    When Clarke advanced to the therapeutic dose of semaglutide, she developed heart palpitations and tachycardia (racing heartbeat).

    “It got to a point where it was like I could feel my heart beating out of my chest,” Clarke said. “It would wake me up in the middle of the night, and I was kind of panicking because I was like, this doesn’t feel right. It feels very scary.”

    Clarke didn’t mention it, but other people who take semaglutide appear to develop what’s becoming known as “Ozempic face,” in which rapid weight loss causes a person’s face to look gaunt, saggy and prematurely aged.

    “When you lose weight so acutely and quickly, you see more of a global facial wasting,” Dr. Paul Jarrod Frank, a New York City dermatologist, told NBC’s TODAY show.

    “It’s not just a wrinkle we’re seeing in one area or a heaviness around the eyes,” Frank continued. “We’re seeing it in the temples, the jaw line, around the mouth, under the eyes.”

    Despite her side effects, Clarke stuck with Ozempic for about a year because the drug was very effective in controlling her diabetes and helping her lose weight.

    Clarke dropped about 10 pounds within a month. By the time she decided to stop taking Ozempic a year later, she’d lost 35 pounds.

    “It was really tempting to continue it because it’s such an easy medication to take,” Clarke said. “It’s once weekly, it’s an injection, it does not hurt that badly at all, barely feels like a pinch.”

    “I just felt like, I kind of want to continue this because I’m seeing really good results on it. But then for the flip side, it was like, even though I’m seeing these great results, I feel awful all the time,” Clarke added. “I don’t feel good, I don’t have any energy, I feel sick and nauseous. And that’s not quality of life.”

    Clarke was worried that she’d regain the weight she lost after she stopped taking Ozempic, but that wasn’t what happened.

    “I actually ended up maintaining my weight for a little while and then even losing a little bit more. So total, I lost about 50 pounds,” Clarke said.

    As demand exceeds supply, some with diabetes go without

    Clarke has described the semaglutide shortages as “really frustrating” on her blog, particularly for people who need the drug to manage their diabetes.

    Wegovy contains a higher dose of semaglutide, because that’s the dose needed to treat obesity as approved by the U.S. Food and Drug Administration.

    Ever since Wegovy arrived on the market, manufacturer Novo Nordisk has struggled to meet demand, prompting off-label prescription of Ozempic for weight loss.

    “There are people who are using it for weight loss for health purposes, and I think that is amazing,” Clarke said. “Especially with my own experience, I know how helpful it can be.”

    But social media has spurred demand by promoting semaglutide as a miracle weight-loss drug, Lofton said.

    Wegovy is meant to help people with weight problems so bad that the extra pounds are harming their health, but semaglutide is instead being used to help people achieve the “perfect body.”

    Clarke noted an “Ozempic challenge” circulating on TikTok.

    “It’s people who are at a pretty normal weight,” Clarke said of the TikTok videos. “Maybe they have like 10 pounds that they want to lose because of some reason. From what I’ve seen, it’s usually vanity purposes.”

    “And so they’re using Ozempic, and I think that has a really big impact on people with diabetes because we’re not able to get the drug at this point,” Clarke said. “There are so many shortages, and there’s a lack of production for Ozempic with this increased demand because people are seeing that it works for weight loss very well.”

    Lofton said that both uses of the drug are legitimate, and what’s really needed is for Novo Nordisk to resolve its production bottleneck and for insurers to cover semaglutide treatment.

    Novo Nordisk has promised to resolve the semaglutide shortages within the first few months of 2023, Lofton said.

    “We have about 40 million people with obesity/overweight, and we have about 11 million people in the U.S. with diabetes,” Lofton said.

    “If the companies can’t meet the demand — which I’m glad the demand is great and people know about these drugs — then we really need to reevaluate how these pharmaceutical companies are allowing us, as well as insurance companies are allowing us, to have access to these much-needed drugs for multiple conditions,” Lofton said.

    More information

    The U.S. Food and Drug Administration has more on shortages of Wegovy and Ozempic.

     

     

    SOURCES: Mila Clarke, blogger and activist; Holly Lofton, MD, obesity medicine specialist, NYU Langone Health, New York City

     

    [ad_2]

    Source link